HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway.

Abstract
Osteosarcoma is one of the most common primary malignant bone tumors in children and adolescents. Some patients continue to have a poor prognosis, because of the metastatic disease. YM529/ONO-5920 is a nitrogen-containing bisphosphonate that has been used for the treatment of osteoporosis. YM529/ONO-5920 has recently been reported to induce apoptosis in various tumors including osteosarcoma. However, the mode of metastasis suppression in osteosarcoma by YM529/ONO-5920 is unclear. In the present study, we investigated whether YM529/ONO-5920 inhibited tumor cell migration, invasion, adhesion, or metastasis in the LM8 mouse osteosarcoma cell line. We found that YM529/ONO-5920 significantly inhibited metastasis, cell migration, invasion, and adhesion at concentrations that did not have antiproliferative effects on LM8 cells. YM529/ONO-5920 also inhibited the mRNA expression and protein activities of matrix metalloproteinases (MMPs). In addition, YM529/ONO-5920 suppressed phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2) and the serine/threonine protein kinase B (Akt) by the inhibition of Ras prenylation. Moreover, U0126, a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, also inhibited LM8 cell migration, invasion, adhesion, and metastasis, as well as the mRNA expression and protein activities of MMP-1, MMP-2, MMP-9, and MT1-MMP. The results indicated that YM529/ONO-5920 suppressed the Ras/MEK/ERK and Ras/PI3K/Akt pathways, thereby inhibiting LM8 cell migration, invasion, adhesion, and metastasis. These findings suggest that YM529/ONO-5920 has potential clinical applications for the treatment of tumor cell metastasis in osteosarcoma.
AuthorsMasanobu Tsubaki, Takao Satou, Tatsuki Itoh, Motohiro Imano, Mitsuhiko Ogaki, Masashi Yanae, Shozo Nishida
JournalToxicology and applied pharmacology (Toxicol Appl Pharmacol) Vol. 259 Issue 3 Pg. 402-10 (Mar 15 2012) ISSN: 1096-0333 [Electronic] United States
PMID22326785 (Publication Type: Journal Article)
CopyrightCopyright © 2012 Elsevier Inc. All rights reserved.
Chemical References
  • Diphosphonates
  • Imidazoles
  • Phosphoinositide-3 Kinase Inhibitors
  • RNA, Messenger
  • YM 529
  • Proto-Oncogene Proteins c-akt
  • Extracellular Signal-Regulated MAP Kinases
  • Mitogen-Activated Protein Kinase Kinases
  • Matrix Metalloproteinases
  • ras Proteins
Topics
  • Animals
  • Cell Adhesion (drug effects)
  • Cell Line, Tumor
  • Cell Movement (drug effects)
  • Diphosphonates (pharmacology)
  • Extracellular Signal-Regulated MAP Kinases (antagonists & inhibitors)
  • Gene Expression Regulation, Neoplastic (drug effects)
  • Imidazoles (pharmacology)
  • Male
  • Matrix Metalloproteinases (genetics, metabolism)
  • Mice
  • Mice, Inbred C3H
  • Mitogen-Activated Protein Kinase Kinases (antagonists & inhibitors)
  • Neoplasm Invasiveness (prevention & control)
  • Neoplasm Metastasis (prevention & control)
  • Osteosarcoma (drug therapy, pathology)
  • Phosphoinositide-3 Kinase Inhibitors
  • Proto-Oncogene Proteins c-akt (antagonists & inhibitors)
  • RNA, Messenger (metabolism)
  • ras Proteins (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: